Biogen acquires RayThera in deal worth up to $1 billion

Shareholders of RayThera volition person an upfront payment, with the full woody worth taxable to summation done payments tied to hitting aboriginal objective and regulatory benchmarks, the institution said. Closing is anticipated successful the 3rd 4th of 2026, pending customary regulatory approvals and different modular conditions. After closing, work for bringing RayThera's assets done development, manufacturing, and planetary commercialization volition transportation to Biogen.

Among the assets changing hands are respective small-molecule cause candidates aimed astatine immune-mediated conditions spanning assorted therapeutic indications. The institution said its astir precocious programme is connected way to statesman Phase 1 investigating nary aboriginal than aboriginal successful the 3rd 4th of this year.

"With this acquisition, we are further deepening our pipeline successful immunology by adding a suite of assets that tin let america to grow into caller illness areas," Priya Singhal, Executive Vice President and Head of Development astatine Biogen, said successful a statement. "We judge these assets tin meaningfully lend to our semipermanent pipeline imaginable and we're excited astir the accidental to rapidly beforehand the archetypal campaigner into the clinic."

Qing Dong, co-founder, Chairman, and CEO of RayThera, said successful a connection that Biogen's "strong planetary improvement capabilities successful immunology" marque it "the earthy fit" to beforehand the programs into Phase 1 and beyond.

RayThera was co-founded by Qing Dong and Gene Hung, M.D., and completed a Series A financing circular co-led by Foresite Capital and OrbiMed Advisors, with information from TTM Capital, according to Pharmaphorum. The 2 co-founders antecedently built and sold 2 different San Diego biotech companies — FronThera and XinThera — to Alumis and Gilead Sciences, respectively, according to Pharmaphorum.

The RayThera woody comes soon aft Biogen completed its acquisition of Apellis Pharmaceuticals, a transaction that added 2 complement-targeting drugs — SYFOVRE and EMPAVELI — to its portfolio successful a woody valued astatine astir $5.3 billion. That acquisition expanded Biogen's beingness successful nephrology and ophthalmology.

Pressure connected Biogen's gross basal — driven successful portion by biosimilar rivals eroding income of the MS cause Tysabri and different halfway products — has intensified the company's propulsion to diversify its pipeline done acquisitions.